• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

PET agent unlocks door to Alzheimer's disease

Publication
Article
Diagnostic ImagingDiagnostic Imaging Vol 32 No 9
Volume 32
Issue 9

A PET agent built around fluorine-18 readily and safely distinguished the brains of Alzheimer's disease patients from those of healthy volunteers in a clinical trial at Johns Hopkins University.

A PET agent built around fluorine-18 readily and safely distinguished the brains of Alzheimer's disease patients from those of healthy volunteers in a clinical trial at Johns Hopkins University.

Dr. Dean F. Wong, a professor of radiology and psychiatry at Johns Hopkins, and colleagues plugged F-18 into a compound known as florbetapir F-18, which is drawn to the beta-amyloid in Alzheimer's plaques. The compound has a half-life of about 110 minutes.

Testing the new compound in humans, Wong and his colleagues recruited 26 volunteers, 11 previously diagnosed with Alzheimer's disease and 15 healthy subjects of similar age who performed normally on cognitive tests. Each volunteer received a florbetapir PET scan, acquired over 90 minutes. The Alzheimer's patients showed significantly more of the agent in their brains than the healthy volunteers with the radiotracer accumulating in regions known to be associated with beta-amyloid deposits.

Recent Videos
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Can 18F-Floutufolastat Bolster Detection of PCa Recurrence in Patients with Low PSA Levels After Radical Prostatectomy?
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.